EpitoGen Technology is a novel epitope/peptide expression platform. The epitope antigen (Epitogen) is fused in the middle of an inert scaffold protein and displayed on the top of the scaffold ideally suited to a number of antigen/antibody-based assays such as ELISA and lateral flow. The technology was developed by Vertebrate Antibodies Ltd in collaboration with researchers from the University of Aberdeen.
The EpitoGen Technology consists of a bioengineered scaffold protein to which a single epitope or multiple epitopes of varying sequences and length can be fused. The hydrophobic tail contained at the N and C terminals will bind preferentially to hydrophobic surfaces and exposing the candidate epitopes to the surface. This arrangement allows for the epitopes to assemble in their native conformation for specific binding to their cognate antibodies.
The scaffold exhibits a compact and structurally rigid core that is monomeric, highly stable, soluble, non-toxic, and capable of to supporting complex peptides. The scaffold is capable of high production levels in prokaryotic cells and contains a purification tag.
EpitoGen Technology efficiently expresses short epitopes to vastly improve antibody tests
Expression of short epitopes in E. coli, conventional approach
– Poor expression
– Poor stability (degradation)
– Aggregation issues
Expression of short epitopes in E. coli, Epitogen approach
– High expression
– Increased stability
– Excellent solubility
Epitopes expressed using conventional approach vs. novel Epitogen Technology approach
Bioengineered scaffold ensures accurate folding of epitopes